Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Cooperations

The German Hodgkin Study Group cooperates closely with the Österreichische Arbeitsgemeinschaft für klinische Pharmakologie und Therapie (ARGE, Austrian Study Group for Clinical Pharmacology and Therapy) and theSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK Swiss Study Group for Clinical Cancer Research). These study groups are recruiting patients from Austria and Switzerland for the GHSG trials and their representative are members of the GHSG’s trial steering committee. The GHSG also maintains close contacts and cooperations with the British National Lymphoma Investigation (BNLI), the Italian Lymphoma Intergroup (ILI) and theEuropean Organisation for Research and Treatment of Cancer (EORTC). The GHSG and the EORTC discuss planned trials and study strategies regularly and also conduct certain trials together. The results of the HDR2 trial for relapsed or refractory Hodgkin lymphoma patients, for example, were published jointly in 2010 (Journ Clin Oncol 28 (34): 5074-5080, 2010).

The GHSG is a member of the Kompetenznetz Maligne Lymphome (KML, Competence Network for Malignant Lymphomas), which unites the leading German research groups and health care institutions in the area of malignant lymphomas. Their joint aim is to ensure optimal treatment, care and information for all lymphoma patients.